ProBioGen and Spica Therapeutics announce a new collaboration
30 Dec 2025
ProBioGen and Spica Therapeutics (Spica) have announced a new collaboration. Under the agreement, ProBioGen will perform cell line development for ST101, Spica’s first clinical development candidate anti-CD163 depleting antibody for oncology.
ST101 is a first-in-class monoclonal antibody designed to selectively deplete immunosuppressive CD163+ tumor-associated macrophages (TAMs). Spica has integrated ProBioGen’s proprietary GlymaxX® GlymaxX® technology to boost antibody-dependent cell-mediated cytotoxicity (ADCC).
This collaboration combines Spica’s innovative macrophage-focused therapeutic approach with ProBioGen’s proven expertise in cell line development and enabling innovative technologies. Together, the partnership provides a strong foundation for advancing ST101 towards future development milestones.
"We are glad to collaborate with Spica Therapeutics on cell line development for ST101. ProBioGen’s CHO.RiGHT® expression platform including our proprietary DirectedLuck® transposase system for precise genetic engineering is designed to support biologics with high performance, high purity, and robust productivity. Incorporating GlymaxX offers an additional layer of functional enhancement aimed at strengthening the therapeutic potential of ST101," said Dr. Gabriele Schneider, Chief Business Officer at ProBioGen.
Dr. Hilde Revets, Director of Non-Clinical Development at Spica Therapeutics added, "This agreement marks an important step for our development candidate ST101. Integrating ProBioGen’s GlymaxX® technology supports our strategy of developing ST101 to deeply deplete immunosuppressive TAMs to remodel the tumor microenvironment, with the aim of boosting responses of cancer patients receiving immunotherapy."